Company: SVREW
Filing Date: 2025-03-21
Form Type: 20-F
Source: 0001013762-25-001028
Chunk: 46

Company: SaverOne 2014 Ltd.
Filing Date: 2025-03-21
Form: 20-F
Item: Item 3
Chunk 46
---

that were developed under IIA programs up to the total amount of grants received, linked to the U. S. dollar and bearing interest at an
annual London Interbank Offered Rate applicable to U. S. dollar deposits. Regardless of any royalty payment, we are further required to
comply with the requirements of the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984,
as amended, and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how, technology
or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the transfer
of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of
the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside
of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those
approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or
development out of Israel.

The
transfer of IIA-supported technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the
value of the transferred technology or know-how, our research and development expenses, the amount of IIA support, the time of completion
of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair our ability to sell
or otherwise transfer our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with
respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction
involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction)
may be reduced by any amounts that we are required to pay to the IIA.

We
have also received a grant from the Israeli Ministry of Economy, or MOE, with respect to certain consulting and marketing activities
conducted outside of Israel. For information, see Note 11b to our audited financial statements.

General
Risk Factors

We
incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial
time to new compliance initiatives.

As
a public company whose ADSs are listed in the United States, we